Search
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigationalPrucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further develo...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesMuraglitazar
go.drugbank.com/drugs/DB06510InvestigationalMuraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesP-57AS3
go.drugbank.com/drugs/DB06569ExperimentalCategories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesNemonoxacin
go.drugbank.com/drugs/DB06600InvestigationalCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the spo...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesAxitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalAxitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumo...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNilvadipine
go.drugbank.com/drugs/DB06712ApprovedNilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InhibitorsSparteine
go.drugbank.com/drugs/DB06727ApprovedWithdrawnSparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not c...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsAniline
go.drugbank.com/drugs/DB06728InvestigationalAniline, phenylamine or aminobenzene is an organic compound with the formula C6H5NH2. Consisting of an amine attached to a benzene ring, aniline is the prototypical aromatic amine. Being a precursor to many industrial chemicals, its main...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates